-
Mashup Score: 150FDA approves osimertinib - 9 month(s) ago
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14Biomarkers in Lung Cancer: Barriers to Implementation | IASLC - 9 month(s) ago
The IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2017 that found one-third of oncologists were unaware of evidence-based gu …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet-
It was an honor to join the one & only great host/expert Dr. @StephenVLiu & amazing colleagues, Drs @DeboraBrunoMD1 @MattSmeltzer in this special @IASLC “Lung Cancer Considered” #Podcast on: “Biomarkers in #LungCancer.” Tune in👇🏼& Plz take the survey. https://t.co/8BbJfDmHtZ https://t.co/JgODj4vO6g https://t.co/fO0KKB1TRX
-
-
Mashup Score: 145FDA approves osimertinib - 9 month(s) ago
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨Hot off the press. The #FDA approves 1st line #Osimertinib WITH chemotherapy for advanced #EGFRm non-small cell #LungCancer. Approval based on #FLAURA2 trial which showed ⬆️#PFS compared to #Osimertinib alone. HR: 0.62 mPFS: 25.5 vs 16.7 months 👇🏼 https://t.co/QRxAgEZgDD https://t.co/FyoOBkvTuP
-
-
Mashup Score: 132FDA approves osimertinib - 9 month(s) ago
FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
🔥🚨Hot off the press. The #FDA approves 1st line #Osimertinib WITH chemotherapy for advanced #EGFRm non-small cell #LungCancer. Approval based on #FLAURA2 trial which showed ⬆️#PFS compared to #Osimertinib alone. HR: 0.62 mPFS: 25.5 vs 16.7 months 👇🏼 https://t.co/QRxAgEZgDD https://t.co/FyoOBkvTuP
-
-
Mashup Score: 30New Simplified Membership Model Offers More Benefits to More Members - 9 month(s) ago
The new model provides all members access to the complete suite of ASCO publications, resources, and programs with applicable discounts still in place for relevant groups.
Source: connection.asco.orgCategories: General Medicine News, Hem/OncsTweet-
🚨🔥Hot off the press @ASCO The American Society of Clinical Oncology announced NEW simplified MEMBERSHIP MODEL that offers MORE benefits to MORE members. Grateful to OUR great #SOCIETY that truly represents the #Oncology Community. Announced changes👇🏼 https://t.co/Tw0eMJ4tNc https://t.co/gHW0m4laYB
-
-
Mashup Score: 10Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM - 10 month(s) ago
Original Article from The New England Journal of Medicine — Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
#LungCancerRx #LCSM @LungCancerRx #ADAURA TRIAL 4/4: Most recently, results of overall survival #OS data were presented in #ASCO23 by Dr @DrRoyHerbstYale & simultaneously published at @NEJM. Link to article⬇️ https://t.co/NKNbvh511d https://t.co/J99EIYoTbT
-
-
Mashup Score: 30The ASCO Postâs Most-Read Articles of 2023 - 11 month(s) ago
NCCN Clinical Practice Guidelines in Oncology: 2023 Updates In 1996, the National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCNâs 28th…
Source: contentsharing.netCategories: General Medicine News, Hem/OncsTweet-
🚨🔥@OncoAlert The 10 most-read #articles of @ASCOPost (the #1 #Oncology Newspaper) in 2023. Great educational articles on practice changing #Trials & @NCCN updates. It’s an #EraOfHope for #Patients with #Cancer. #KnowledgeConquersCancer @ASCO 👇🏼 https://t.co/l62lNSWzCB https://t.co/XdLJq6X94d
-
-
Mashup Score: 10Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM - 11 month(s) ago
Original Article from The New England Journal of Medicine — Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
#LungCancerRx #LCSM @LungCancerRx #ADAURA TRIAL 4/4: Most recently, results of overall survival #OS data were presented in #ASCO23 by Dr @DrRoyHerbstYale & simultaneously published at @NEJM. Link to article⬇️ https://t.co/NKNbvh511d https://t.co/J99EIYoTbT
-
-
Mashup Score: 82
Original Article from The New England Journal of Medicine — Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
🔥🚨@OncoAlert Hot off the press. Just published @NEJM Results of #FLAURA2, phase 3 trial of 1st line #Osimertinib with or without #Chemotherapy in patients with #EGFR mutated advanced non-small cell #LungCancer (#NSCLC). 👇🏼 https://t.co/NXEMU5ZSQi https://t.co/oAQEVidB9G
-
-
Mashup Score: 3Rami Manochakian: A special supplement highlighting major data from the IASLC 2023 - Oncodaily | Oncology News, Insights, Stories - 12 month(s) ago
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: A special supplement highlighting major data from the IASLC 2023 - @RManochakian @ASCOPost @IASLC https://t.co/Bp3UeWfNeu…
-
🔥🚨Hot off the press. The #FDA approves 1st line #Osimertinib WITH chemotherapy for advanced #EGFRm non-small cell #LungCancer. Approval based on #FLAURA2 trial which showed ⬆️#PFS compared to #Osimertinib alone. HR: 0.62 mPFS: 25.5 vs 16.7 months 👇🏼 https://t.co/QRxAgEZgDD https://t.co/FyoOBkvTuP